Quintiles and The Medical Affairs Company (TMAC) have entered a collaboration expanding each company’s medical affairs-related offerings for customers in the U.S. Quintiles will add TMAC’s medical science liaison (MSL) capabilities to its field-based medical solutions, with the goal of providing additional expertise to engage and encourage increased knowledge of research, products and devices. The collaboration also allows TMAC to leverage Quintiles’ clinical educators to facilitate ongoing education of healthcare professionals, patients and caregivers.
 
“Today, more than ever before, biopharma companies looking to commercialize products in the U.S. are focused on demonstrating the value and benefits of their products to an increasingly diverse range of stakeholders,” said Daryl Gaugler, senior vice president, Commercial Solutions at Quintiles. “As this stakeholder landscape and its requirements continue to evolve, we are delighted to be working alongside a company like TMAC to offer the full spectrum of commercialization services, with an integrated approach to sales, medical science liaison, clinical education and market entry.”
 
“Requirements for medical affairs activities are expanding across the product life cycle,” said Evan Demestihas, M.D., chief executive officer, TMAC. “Working with companies like TMAC and Quintiles provides customers with benefits in terms of strategic oversight, speedy deployment and operational flexibility, while maintaining the discipline-specific and therapy area expertise that are essential to medical affairs teams. Through this collaboration, we believe Quintiles and TMAC will offer customers turn-key field commercialization capabilities that are unmatched in our industry.”